Advisors Capital Management LLC Purchases 5,254 Shares of Eli Lilly and Company (NYSE:LLY)

Advisors Capital Management LLC lifted its stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 102.2% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 10,393 shares of the company's stock after acquiring an additional 5,254 shares during the period. Advisors Capital Management LLC's holdings in Eli Lilly and Company were worth $8,023,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in the company. Highline Wealth Partners LLC raised its holdings in shares of Eli Lilly and Company by 80.0% during the 4th quarter. Highline Wealth Partners LLC now owns 45 shares of the company's stock valued at $35,000 after buying an additional 20 shares in the last quarter. Kovitz Investment Group Partners LLC raised its stake in shares of Eli Lilly and Company by 117.1% during the third quarter. Kovitz Investment Group Partners LLC now owns 46,132 shares of the company's stock worth $41,000 after acquiring an additional 24,879 shares in the last quarter. FPC Investment Advisory Inc. lifted its holdings in shares of Eli Lilly and Company by 358.3% in the 4th quarter. FPC Investment Advisory Inc. now owns 55 shares of the company's stock worth $45,000 after acquiring an additional 43 shares during the last quarter. Prudent Man Investment Management Inc. purchased a new stake in shares of Eli Lilly and Company in the 4th quarter valued at $48,000. Finally, Compass Financial Services Inc bought a new position in shares of Eli Lilly and Company during the 4th quarter valued at $50,000. Institutional investors own 82.53% of the company's stock.

Eli Lilly and Company Stock Up 0.3 %

Shares of Eli Lilly and Company stock traded up $2.20 during midday trading on Tuesday, hitting $756.55. The company had a trading volume of 2,439,271 shares, compared to its average volume of 3,387,075. Eli Lilly and Company has a 52-week low of $677.09 and a 52-week high of $972.53. The company has a debt-to-equity ratio of 2.00, a quick ratio of 0.97 and a current ratio of 1.15. The stock has a market capitalization of $717.34 billion, a P/E ratio of 64.61, a P/E/G ratio of 1.40 and a beta of 0.51. The company has a 50 day moving average of $835.24 and a 200 day moving average of $822.00.

Remove Ads

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its earnings results on Thursday, February 6th. The company reported $5.32 EPS for the quarter, missing analysts' consensus estimates of $5.45 by ($0.13). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. On average, equities analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

LLY has been the subject of several analyst reports. StockNews.com upgraded shares of Eli Lilly and Company from a "hold" rating to a "buy" rating in a research report on Friday, February 7th. Guggenheim reduced their price target on Eli Lilly and Company from $973.00 to $928.00 and set a "buy" rating on the stock in a research report on Monday. Morgan Stanley lowered their price objective on Eli Lilly and Company from $1,146.00 to $1,124.00 and set an "overweight" rating for the company in a research report on Wednesday, April 9th. Truist Financial raised their target price on shares of Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the stock a "buy" rating in a report on Monday, February 3rd. Finally, The Goldman Sachs Group raised shares of Eli Lilly and Company from a "neutral" rating to a "buy" rating and dropped their price target for the company from $892.00 to $888.00 in a research report on Tuesday, April 8th. Two equities research analysts have rated the stock with a hold rating and eighteen have given a buy rating to the stock. Based on data from MarketBeat, Eli Lilly and Company presently has a consensus rating of "Moderate Buy" and an average target price of $1,012.00.

Insiders Place Their Bets

In related news, CAO Donald A. Zakrowski sold 1,000 shares of the stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $818.24, for a total transaction of $818,240.00. Following the sale, the chief accounting officer now directly owns 5,840 shares of the company's stock, valued at $4,778,521.60. This trade represents a 14.62 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 0.13% of the company's stock.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.